DocumentRX-4173
Issued
Read3 min

FDA approves perioperative Imfinzi-Padcev regimen in bladder cancer

FDA approval gives cisplatin-ineligible or cisplatin-refused MIBC patients a perioperative Imfinzi-Padcev option; VOLGA showed a 49% event-risk cut and 42% lower mortality.

TAG V-5532 · 589 words on the filing

AstraZeneca secures FDA approval for Imfinzi combo in MIBC - Pharmaceutical Technology
AstraZeneca secures FDA approval for Imfinzi combo in MIBC - Pharmaceutical TechnologyEngin_Akyurt / pixabay

Summary of findings

  • FDA approved Imfinzi plus Padcev for cisplatin-ineligible or cisplatin-refused adult MIBC.
  • VOLGA reduced the composite event risk by 49% and the risk of death by 42%.
  • Two-year event-free survival reached 64% versus 45%; overall survival reached 78% versus 69%.
  • Grade 3 and 4 adverse events occurred in 64% versus 44%, with no new safety signals reported.
  • The 695-patient trial remains under review in the EU and Japan; about 16,000 US patients are expected to receive MIBC treatment in 2026.

By Olivia Hart

The FDA has approved AstraZeneca’s perioperative Imfinzi–Padcev regimen after the VOLGA trial cut the composite risk of disease progression, recurrence, omitted surgery or death by 49% in adults with muscle-invasive bladder cancer who cannot receive or have refused cisplatin-based chemotherapy.

What does this approval change for patients unable or unwilling to take cisplatin?

The clearance adds an approved pre- and postoperative option for this group. Padcev (enfortumab vedotin), an Astellas Pharma and Pfizer drug, combines with Imfinzi (durvalumab) neoadjuvantly before radical cystectomy. Single-agent Imfinzi then follows as adjuvant therapy. The sequence keeps surgery inside the treatment pathway rather than relying on surgery alone.

Dave Fredrickson, executive vice president of AstraZeneca’s oncology haematology business unit, said: “Today’s approval offers a novel Imfinzi-based regimen that almost halved the risk of disease recurrence and reduced the risk of death by 42% in the VOLGA trial, allowing physicians to optimise treatment for patients in this curative-intent setting.

He added: “As our third bladder cancer indication in two years, this approval reinforces Imfinzi as an immunotherapy backbone across muscle-invasive and non-muscle-invasive disease.”

The FDA granted clearance under priority review, based on findings from the multicentre VOLGA Phase III study (NCT04960709). The 695-patient trial compared the perioperative regimen with radical cystectomy with or without approved adjuvant treatment. The New England Journal of Medicine published the study, and the data were presented at the 2026 European Society for Medical Oncology Congress.

VOLGA efficacy and safety findings

The perioperative regimen reduced the composite risk of disease progression, recurrence, omitted surgery or death by 49% versus the control treatment. The control comprised radical cystectomy with or without an approved adjuvant regimen.

Estimated two-year event-free survival reached 64% with the Imfinzi–Padcev sequence, compared with 45% in the control arm. Median event-free survival in the control arm stood at 12.1 months.

Overall survival results showed a 42% reduction in the risk of death. Estimated two-year overall survival reached 78% with the regimen, compared with 69% in the control arm.

Grade 3 and 4 adverse events arising from any cause occurred in 64% of patients treated with the combination, compared with 44% in the comparator arm. The trial reported no new safety signals. Patient-reported quality of life was maintained following surgical intervention.

Muscle-invasive tumours account for roughly one-quarter of all bladder cancer cases, with approximately 16,000 people in the US expected to receive treatment in 2026.

Impaired renal function or other comorbidities prevent up to 50% of patients from tolerating cisplatin-based chemotherapy. That constraint left radical cystectomy alone as the historical standard despite frequent recurrences.

For treatment centres, the practical change is an FDA-approved perioperative option for a group for which surgery alone was the historical standard. Treatment follows a defined sequence: neoadjuvant Imfinzi plus Padcev, radical cystectomy and then adjuvant single-agent Imfinzi. The approval therefore adds choice without removing surgery from the regimen or its associated safety burden.

Outside the US, regulatory applications based on the 695-patient trial remain under review in the European Union, Japan and other territories.

In May 2026, AstraZeneca received FDA approval for Imfinzi with Bacillus Calmette-Guérin induction and maintenance therapy for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer. Imfinzi also holds multiple US approvals across lung, bladder, gastrointestinal and gynaecological cancers.

The pending European Union and Japan decisions now sit alongside the two US bladder-cancer approvals built on Imfinzi.

via FDA industry wire (Google News) (Source)

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

13 articles

Linked filings

  1. K-4971
  2. C-4460
  3. C-6506
  4. P-9899
  5. E-2578

« Previous filing